Entering text into the input field will update the search result below

FDA paves way for Omeros to start Phase II trials of OMS721

Apr. 03, 2014 7:40 AM ETOmeros Corporation (OMER) StockBy: Yigal Grayeff, SA News Editor
  • The FDA has approved Omeros' (NASDAQ:OMER) investigational new drug application for the company's OMS721 treatment for complementmediated thrombotic microangiopathies (TMAs), which are rare, debilitating and life-threatening disorders characterized by multiple clots in the body's organs, most commonly the kidney and brain.
  • The FDA's authorization paves the way for Omeros to start Phase II trials of OMS721, the first one of which is planned for this quarter. (PR)

Recommended For You

More Trending News

About OMER Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
OMER--
Omeros Corporation